Is there a role for pharmacogenetics in the dosing of fentanyl?

Written by Koolen SLW & Van der Rijt CCD

Fentanyl is one of the most frequently used opioids for the treatment of severe chronic and acute cancer-related pain. It is the opioid of first choice in patients with renal impairment [1] and seems to be related with a lower incidence of severe constipation than other opioids [2]. Furthermore, it is available in various patient-friendly products for different clinical situations. The fentanyl patches result in continuous delivery of fentanyl during 72 h and are therefore ideal for the treatment of chronic severe pain. The formulations for buccal, sublingual or nasal delivery of fentanyl are, on the contrary, ideal for the...

To view this content, please register now for access

It's completely free